Ebola Vaccines

Authored by
Last reviewed
November 25, 2022

Ebola Vaccines 2022

Zaire Ebola vaccines have been approved by the U.S. FDA, European Medicines Agency (EMA), World Health Organization (WHO), and the U.K since 2019 to protect people from contracting the Ebola virus disease (EVD). 

Ebola vaccine technologies include replication-deficient adenovirus vectors, replication-competent vesicular stomatitis, human parainfluenza vectors, and virus-like nanoparticle preparations.

Zaire Ebolavirus Vaccines

As of November 2022, Zaire Ebola vaccines and antibody treatments remain in limited distribution in the U.S. Contact your local or state health department for availability requirements. The U.S. CDC published the 'current state of Ebola vaccines on March 8, 2022, and the VIS was updated on June 30, 2022.

In addition, the U.S. CDC's Advisory Committee on Immunization Practices extended its Ervebo vaccination recommendations on February 25, 2022, to include two groups: healthcare personnel at specific pathogens treatment centers, laboratories, and support staff at Laboratory Response Network facilities.

Merck's Ervebo (rVSVΔG-ZEBOV-GP) is a recombinant, replication-competent Zaire Ebolavirus vaccine Approved by the U.S. FDA.

J&J's Ebola Vaccine Regimen Zabdeno and Mvabea is a prime-boost vaccination approach and contains an antigen from the Sudan species first approved by the EMA.

CanSinoBio's Ad5-EBOV is an adenovirus type 5 vector-based Zaire Ebola virus vaccine.

cAd3-EBOZ/MVA-BN-Filo was developed by the U.S. NIAID/NIH in collaboration with Okairos and is now licensed to the Sabin Vaccine Institute, which has licensed the cAd3 platform to develop vaccines against the Sudan virus. The vaccine platform is similar to Zabdeno/Mvabea; however, the first dose consists of an attenuated chimpanzee adenovirus to address issues associated with preexisting immunity to the vector, such as the case with Zabdeno. 

Sudan Ebolavirus Vaccine Candidates

As of November 25, 2022, there are no approved vaccines protecting people against Sudan Ebolavirus (SUDV).

The WHO stated on November 16, 2022, three candidate vaccines are under consideration: 

A bivalent adenovirus vectored vaccine (biEBOV) which consists of the replication-deficient simian adenovirus vector ChAdOx1 encoding two antigens: EBOV glycoprotein (Zaire) and SUDV glycoprotein (Sudan) developed by the University of Oxford and the Jenner Institute UK. The ChAdOx1 biEBOV vaccine is targeted against the Zaire and Sudan species of Ebolavirus and is conducting a phase 1 study.

A monovalent adenovirus vectored vaccine consisting of the simian adenovirus vector ChAd3 encoding the SUDV glycoprotein (ChAd3-SUDV) and produced by the Sabin Vaccine Institute USA. Sabin's Ebola Sudan vaccine (ChAd3-SUDV) has been evaluated in Phase 1 clinical trial in the U.S. and is planning a Phase 2 trial.

A monovalent vaccine that consists of the vesicular stomatitis virus (VSV) as the backbone with the VSV-G gene replaced with the Ebola-GP gene from the Sudan strain (VSV-SUDV) from the International Aids Vaccine Initiative (IAVI). Merck's Sudan ebolavirus vaccine candidate is undergoing a "fill and finish" process that puts the bulk product into vials. Merck and IAVI expect that process to take to be completed in 2022.

IAVI's rVSV Sudan ebolavirus vaccine candidate (rVSVΔG-SUDV-GP) is in the preclinical phase of the research stage and preparing for human clinical trials.

The Serum Institute of India plans to manufacture about 30,000 doses of an experimental Sudan Ebolavirus vaccine.

INOVA's INO-4201 is composed of a precisely designed DNA plasmid injected intradermally followed by electroporation using a proprietary smart device, which delivers the DNA plasmid directly into cells in the body and is intended to produce a well-tolerated immune response; currently conducting phase 1b clinical research.

GeoVax Labs, Inc.'s vectored vaccine MVA-VLP-SUDV was generated against Sudan Ebolavirus, combining the advantages of the immunogenicity of a live attenuated vaccine vector (MVA) with the authentic conformation of virus-like particles. Data published on July 25, 2022, demonstrate single dose protection and potency of the MVA-VLP platform for use in emergencies to contain outbreaks.

Soligenix, Inc. is proposing the develop SuVax™, a single-vial, adjuvanted, heat-stable subunit vaccine to prevent filovirus infection for use in the event of a Sudan ebolavirus outbreak.

Human Monoclonal Antibody For Ebolavirus

The U.S. NIH says monoclonal antibodies (mAbs) are made in a laboratory to fight a particular infection and are administered during an infusion. mAbs are different than vaccines.

Ebanga (mAb114) is a human IgG1 MAb targeted to the Zaire ebolavirus glycoprotein, available in a lyophilized form. The WHO issued a strong recommendation in August 2022. On December 22, 2020, Ridgeback Biotherapeutics L.P. confirmed that the U.S. FDA approved Ebanga to treat Zaire Ebola. 

On May 2, 2022, the U.S. FDA issued a priority review voucher for a material threat medical countermeasure (MCM) product application for INMAZEB (atoltivimab, maftivimab, and odesivimab-ebgn), Zaire ebolavirus, manufactured by Regeneron Pharmaceuticals, Inc. As a result, the FDA approved Inmazed in October 2020.

On October 14, 2020, the U.S. Food and Drug Administration (FDA) approved an antibody cocktail from Regeneron that's been shown to reduce Ebola-related mortality rates. The treatment, known as REGN-EB3, is a mixture of (3) monoclonal antibodies (atoltivimab, maftivimab, and odesivimab-ebgn) and is marketed under the brand name Inmazeb. Inmazeb is indicated to treat infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.

The U.S. Administration for Strategic Preparedness and Response announced on October 4, 2022, a $109.8 million contract with Mapp Biopharmaceutical Inc. for the advanced development and potential purchase of a mAb therapy to treat Sudan Ebolavirus.

Sudan Ebolavirus Outbreak 2022

On September 20, 2022, Uganda's health authorities declared an outbreak of Ebola disease caused by the Sudan ebolavirus. Additional SUDV outbreak in Uganda news is posted at Vax-Before-Trave.com/Ebola.

Ebola Vaccine News 2022

November 16, 2022 - The WHO confirmed three candidate Sudan Ebolavirus vaccines for a proposed clinical trial in the Republic of Uganda should be shipped to the country next week, confirmed the WHO.

November 2, 2022 - AIM ImmunoTech Inc. announced the U.S. FDA had granted Orphan Drug Designation to Ampligen® (rintatolimod) for treating Ebola virus disease.

October 27, 2022 - Soligenix, Inc. announced today that the Company had been invited to submit a complete contract proposal for developing single-vial, adjuvanted, heat-stable subunit vaccines to prevent filovirus infection from Sudan and Marburg virus infections.

October 25, 2022 - IAVI and Merck entered into an agreement that could enable IAVI to accelerate the entry of a Sudan ebolavirus (SUDV) vaccine candidate into human clinical evaluation. As a result, Merck hopes to be able to deliver approximately 55,000 doses by the end of 2022.

October 23, 2022 -   Jon Cohen with Science.org reported Merck Inc. had about 100,000 doses of a Sudan ebolavirus vaccine candidate.

October 17, 2022 - The Serum Institute of India confirmed plans to manufacture about 30,000 doses of an experimental Sudan Ebolavirus vaccine by the end of November 2022.